Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3085379

CC1(C)CC=C(c2ncccc2N)CC1.O=C(O)C(F)(F)F

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 11/20 0.40
TBK1 Q9UHD2 1/20 0.35
TRPV1 Q8NER1 3/20 0.33
KDM5B Q9UGL1 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PRKCA P17252 2/20 0.33
GSK3B P49841 2/20 0.33
PRKCQ Q04759 2/20 0.33
KIT P10721 1/20 0.32
PRKCG P05129 1/20 0.32
PRKCB P05771 1/20 0.32
JMJD7 P0C870 1/20 0.32
PRKCH P24723 1/20 0.32
PRKCE Q02156 1/20 0.32
PRKCD Q05655 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3083005 0.88 KDM5B (0.37) CSF1RTBK1KDM5B
Trifluoroacetic Acid SCHEMBL3085377 0.86 CSF1R (0.39) CSF1RTBK1KDM5BL3MBTL1ALDH1A1
Trifluoroacetic Acid SCHEMBL3078168 0.78 FFAR2 (0.41) CSF1RTRPV1L3MBTL1
SCHEMBL3093923 0.77 PARP1 (0.39) CSF1RTBK1KDM5BALDH1A1
Trifluoroacetic Acid SCHEMBL2942019 0.75 CSF1R (0.41) CSF1RKIT
Trifluoroacetic Acid SCHEMBL3070940 0.70 PTPN11 (0.41) TRPV1L3MBTL1PRKCAGSK3BPRKCQ
Trifluoroacetic Acid SCHEMBL18297743 0.69 CSF1R (0.40) CSF1RKIT
SCHEMBL12078632 0.69 MAP4K4 (0.37) CSF1RTBK1KDM5BKIT
Trifluoroacetic Acid SCHEMBL2944022 0.69 CSF1R (0.35) CSF1RTRPV1KIT
Trifluoroacetic Acid SCHEMBL27758920 0.68 SMN1; SMN2 (0.49) L3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP claimed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US disclosed
EP-2016057-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-21 EP disclosed
WO-2007123516-A1 C-FMS KINASE INHIBITORS JANSSEN PHARMACEUTICA, N.V. (BE) 2007-11-01 WO disclosed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER CSF1R 111/4885TBK1 505/4885TRPV1 3361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.